Genome-Edited T Cell Therapies

Giorgio Ottaviano; Waseem Qasim

doi:10.1016/j.hoc.2022.03.006

Genome-Edited T Cell Therapies

Hematol Oncol Clin North Am. 2022 Aug;36(4):729-744. doi: 10.1016/j.hoc.2022.03.006. Epub 2022 Jun 27.

Authors

Giorgio Ottaviano¹, Waseem Qasim²

Affiliations

¹ Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute of Child Health, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.
² Infection, Immunity & Inflammation Department, UCL Great Ormond Street Institute of Child Health, University College London Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. Electronic address: [email protected].

PMID: 35773047
DOI: 10.1016/j.hoc.2022.03.006

Abstract

Chimeric antigen receptor (CAR) T-cells are widely being investigated against malignancies, and allogeneic 'universal donor' CAR-T cells offer the possibility of widened access to pre-manufactured, off-the-shelf therapies. Different genome-editing platforms have been used to address human leukocyte antigen (HLA) barriers to generate universal CAR-T cell therapy and early applications have been reported in children and adults against B cell malignancies. Recently developed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based systems and related technologies offer the prospect of enhanced cellular immunotherapies for a wider range of hematological malignancies.

Keywords: Base editor; CRISPR/Cas9; Chimeric antigen receptor; Cytidine deamination; Genome editing; T cell therapies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems*
Child
Gene Editing / methods
Humans
Immunotherapy, Adoptive / methods
Neoplasms* / therapy
T-Lymphocytes

Grants and funding

MR/S019022/1/MRC_/Medical Research Council/United Kingdom